JP2013541536A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541536A5
JP2013541536A5 JP2013531796A JP2013531796A JP2013541536A5 JP 2013541536 A5 JP2013541536 A5 JP 2013541536A5 JP 2013531796 A JP2013531796 A JP 2013531796A JP 2013531796 A JP2013531796 A JP 2013531796A JP 2013541536 A5 JP2013541536 A5 JP 2013541536A5
Authority
JP
Japan
Prior art keywords
substituted
compound
unsubstituted
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013531796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541536A (ja
JP5998145B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/053808 external-priority patent/WO2012044727A2/en
Publication of JP2013541536A publication Critical patent/JP2013541536A/ja
Publication of JP2013541536A5 publication Critical patent/JP2013541536A5/ja
Application granted granted Critical
Publication of JP5998145B2 publication Critical patent/JP5998145B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013531796A 2010-10-01 2011-09-29 ピリミジン誘導体の製造プロセス Active JP5998145B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38872110P 2010-10-01 2010-10-01
US61/388,721 2010-10-01
US201161494915P 2011-06-09 2011-06-09
US61/494,915 2011-06-09
PCT/US2011/053808 WO2012044727A2 (en) 2010-10-01 2011-09-29 Manufacturing process for pyrimidine derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015246501A Division JP2016128414A (ja) 2010-10-01 2015-12-17 ピリミジン誘導体の製造プロセス
JP2015246502A Division JP2016106091A (ja) 2010-10-01 2015-12-17 ピリミジン誘導体の製造プロセス

Publications (3)

Publication Number Publication Date
JP2013541536A JP2013541536A (ja) 2013-11-14
JP2013541536A5 true JP2013541536A5 (cg-RX-API-DMAC7.html) 2014-11-13
JP5998145B2 JP5998145B2 (ja) 2016-09-28

Family

ID=44773179

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013531796A Active JP5998145B2 (ja) 2010-10-01 2011-09-29 ピリミジン誘導体の製造プロセス
JP2015246501A Pending JP2016128414A (ja) 2010-10-01 2015-12-17 ピリミジン誘導体の製造プロセス
JP2015246502A Pending JP2016106091A (ja) 2010-10-01 2015-12-17 ピリミジン誘導体の製造プロセス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015246501A Pending JP2016128414A (ja) 2010-10-01 2015-12-17 ピリミジン誘導体の製造プロセス
JP2015246502A Pending JP2016106091A (ja) 2010-10-01 2015-12-17 ピリミジン誘導体の製造プロセス

Country Status (30)

Country Link
US (3) US9181215B2 (cg-RX-API-DMAC7.html)
EP (2) EP3040333B1 (cg-RX-API-DMAC7.html)
JP (3) JP5998145B2 (cg-RX-API-DMAC7.html)
KR (2) KR20130119928A (cg-RX-API-DMAC7.html)
CN (3) CN104945373A (cg-RX-API-DMAC7.html)
AR (1) AR083213A1 (cg-RX-API-DMAC7.html)
AU (4) AU2011308856B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013007123B1 (cg-RX-API-DMAC7.html)
CA (1) CA2813333C (cg-RX-API-DMAC7.html)
CL (2) CL2013000850A1 (cg-RX-API-DMAC7.html)
CO (1) CO6700837A2 (cg-RX-API-DMAC7.html)
DK (1) DK3040333T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012596A (cg-RX-API-DMAC7.html)
ES (1) ES2699951T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300080A (cg-RX-API-DMAC7.html)
HU (1) HUE041326T2 (cg-RX-API-DMAC7.html)
IL (3) IL225113A (cg-RX-API-DMAC7.html)
LT (1) LT3040333T (cg-RX-API-DMAC7.html)
MX (1) MX354482B (cg-RX-API-DMAC7.html)
MY (1) MY160785A (cg-RX-API-DMAC7.html)
NZ (1) NZ608285A (cg-RX-API-DMAC7.html)
PE (1) PE20140002A1 (cg-RX-API-DMAC7.html)
PH (2) PH12013500579A1 (cg-RX-API-DMAC7.html)
PL (1) PL3040333T3 (cg-RX-API-DMAC7.html)
PT (1) PT3040333T (cg-RX-API-DMAC7.html)
RU (2) RU2015150728A (cg-RX-API-DMAC7.html)
SG (1) SG188439A1 (cg-RX-API-DMAC7.html)
SI (1) SI3040333T1 (cg-RX-API-DMAC7.html)
TW (1) TWI540133B (cg-RX-API-DMAC7.html)
WO (1) WO2012044727A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726074B1 (en) 2011-07-01 2018-04-04 Novartis AG Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
AU2013336807B2 (en) * 2012-10-23 2016-10-27 Novartis Ag Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン
US9318944B2 (en) 2013-04-29 2016-04-19 Rockwell Automation Technologies, Inc. Methods and apparatus for active front end filter capacitor degradation detection
US9294005B2 (en) 2013-10-01 2016-03-22 Rockwell Automation Technologies, Inc. Method and apparatus for detecting AFE filter capacitor degradation
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
ES2713452T3 (es) * 2014-04-22 2019-05-21 Univ Basel Proceso de fabricación para derivados de triazina, pirimidina y piridina
CN105085476B (zh) * 2014-11-24 2018-03-09 苏州晶云药物科技有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法
CN107001348B (zh) * 2014-12-17 2019-10-11 上海海雁医药科技有限公司 2-吗啉-4,6-二取代的嘧啶衍生物、其制法与医药上的用途
US9481665B2 (en) * 2015-03-13 2016-11-01 Yong Xu Process for preparing PI3K inhibitor buparsilib
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
CN106543140A (zh) * 2015-09-21 2017-03-29 苏州晶云药物科技有限公司 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法
MY196817A (en) * 2015-12-16 2023-05-03 Genentech Inc Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN107793394A (zh) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 一种生产选择性pi3k抑制剂的系列关键中间体
CN110016142B (zh) * 2019-04-30 2021-08-03 合肥工业大学 一种含嘧啶硼酸结构的硅油及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124476A (en) 1998-04-17 2000-09-26 Symyx Technologies, Inc. Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates
CN1735598A (zh) * 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008098058A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
AU2010247397B2 (en) * 2009-05-15 2012-07-12 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound

Similar Documents

Publication Publication Date Title
JP2013541536A5 (cg-RX-API-DMAC7.html)
RU2013120326A (ru) Способ получения пиримидиновых производных
US10000496B2 (en) Compositions useful for treating disorders related to kit and PDGFR
JP2024012540A (ja) B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP6290788B2 (ja) 4−クロロ−2−フルオロ−3−置換−フェニルボロン酸ピナコールエステルの形成方法およびその使用方法
TW202026271A (zh) 小分子pd-1/pd-l1抑制劑、其與pd-l1抗體的藥物組合物及其應用
JP6457623B2 (ja) 2,4−二置換7H−ピロロ[2,3−d]ピリミジン誘導体、その製造方法および医薬における使用
KR101744033B1 (ko) 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
RU2012150759A (ru) Пирроло[2,3-b]пиридиновые производные в качестве ингибиторов протеинкиназ
TW201538494A (zh) 2,4-二取代苯-1,5-二胺衍生物及其應用以及由其製備的藥物組合物和藥用組合物
TW201806593A (zh) 含有ep拮抗藥與免疫核查點阻礙藥而成之組合
TW201920196A (zh) 作為vanin抑制劑之雜芳族化合物
JP7106659B2 (ja) インドール-2、3-ジオキシゲナーゼ阻害剤としてのスピロ化合物
Fan et al. Direct Pd-catalyzed benzylation of highly electron-deficient perfluoroarenes
CN117677607A (zh) 芳基酰胺衍生物的制造方法
JP6632127B2 (ja) トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
CA2610776C (en) Process for production of mono-substituted alkylated compound using aldimine or derivative thereof
TW201708170A (zh) 1,2-二環丙基乙基苯酚及其光學異構物的製備方法
US10858383B2 (en) Remote heteroaryl alkenylation with catalytic bifunctional template
JPWO2015115519A1 (ja) ビピリジル化合物
TWI631128B (zh) 觸媒、醯胺鍵的形成方法、以及醯胺化合物的製造方法
CN104496995A (zh) 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
JP4083028B2 (ja) アリールボラン化合物の製造方法
WO2008007670A1 (en) Fluoroboron compound, aminomethylating agent for aromatic ring comprising the compound, and process for production of compound having aminomethyl-aromatic ring using the aminomethylating agent
JP2019524783A (ja) ジフルオロアリルホウ酸エステルの製造方法及びその使用